Stratistics MRC에 따르면 세계의 외과용 스네어 시장은 2025년 19억 달러를 차지하며 예측 기간 동안 CAGR 5.8%로 성장해 2032년에는 28억 달러에 이를 것으로 예측됩니다.
외과용 스네어는 신체의 조직을 절제, 회수, 조작하기 위한 저침습 처치에 사용되는 특수한 의료기기입니다. 내시경 수술에 일반적으로 사용되는 외과용 스네어는 외상을 최소화하고 회복 시간을 단축하며 임상 현장에서의 수술 효율을 높이면서 정확하고 제어된 조직의 제거를 가능하게 합니다.
WHO에 따르면 암은 사망 원인의 제1위이며, 세계 약 1,000만명이 사망하고 있습니다.
만성 질환 증가
대장암, 염증성 장질환, 소화관 폴립 등의 만성질환의 세계 부담 증가는 외과용 스네어 수요를 크게 밀어 올리고 있습니다. 외과용 스네어의 사용은 폴립 절제 및 조직 샘플링에 필수적입니다. 따라서 이 만성 질환의 급증은 낮은 침습적 절차를 채택하는 의료 시스템에 압력을 수술 스네어 채용에 연료를 공급하고 있습니다.
고급 외과용 스네어의 높은 비용
외과용 스네어에는 강화된 소재, 인체공학을 기반으로 한 디자인 또는 회전 가능한 첨단과 같은 혁신적인 기능이 내장되어 있기 때문에 제조 및 조달에 비용이 많이 드는 경향이 있습니다. 의료 시설에서는 이러한 도구에 투자하기가 어렵고 대신 기능이 적은 저비용 대체품을 선택할 수 있습니다.
미개척 신흥 시장 진출
신흥국의 급속한 도시화, 건강 관리 인프라 개선, 소화관 건강에 대한 의식 증가는 시장 성장의 큰 기회가 될 것입니다. 이 지역에서 의료 관광이 성장함에 따라 스네어와 같은 저침습 수술기구 수요가 높아지고 시장에의 침투와 브랜드 인지가 깊어질 것으로 예측됩니다.
엄격한 상환 정책
보험 제한과 복잡한 승인 프로세스는 병원이 고비용 내시경 도구에 투자하는 것을 망설일 수 있습니다. 정부와 보험사가 비용 효율적인 치료법을 중시하는 가운데, 제조업체는 자사 제품의 폭넓은 채용을 확보하기 위해 규제상의 장애물을 극복해야 하며, 시장의 성장을 방해하고 있습니다.
COVID-19의 대유행은 외과용 스네어 시장을 혼란시키고 공급망에 영향을 주었고 선택적 치료를 늦추었습니다. 또한, 유행은 기술의 진보를 가속화하고, 제조업체는 진화하는 헬스케어 요구에 대응하기 위해, 보다 효율적이고 비용 효율적인 외과용 스네어의 개발을 촉구했습니다.
예측 기간 동안 재사용할 수 있는 외과용 스네어 부문이 최대화될 전망
재사용 가능한 외과용 스네어 부문은 비용 효율성과 임상 현장에서의 장기적인 사용성으로 인해 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예측됩니다. 이 스네어는 반복적인 치료로 재사용이보다 경제적이되는 대량으로 사용되는 병원에서 선호되는 경우가 많습니다.
예측 기간 동안 콜드 스네어 부문의 CAGR이 가장 높을 것으로 예상
예측 기간 동안 전기 암을 사용하지 않고 작은 폴립을 절제할 수 있는 이점에서 콜드 스네어 부문이 가장 높은 성장률을 나타낼 것으로 예측됩니다.
예측 기간 중 아시아태평양은 인구 급증, 소화기 질환 유병률 증가, 암 조기 발견에 대한 의식 증가 등을 배경으로 최대 시장 점유율을 차지할 것으로 예측됩니다.
예측 기간 동안 북미가 가장 높은 CAGR을 나타낼 것으로 예측되고 있습니다. 또, 주요 기업에 의한 지속적인 기술 혁신과 강력한 연구 개발 자금도 급성장에 기여하고 있습니다.
According to Stratistics MRC, the Global Surgical Snare Market is accounted for $1.9 billion in 2025 and is expected to reach $2.8 billion by 2032 growing at a CAGR of 5.8% during the forecast period. Surgical snare is a specialized medical device used in minimally invasive procedures to excise, retrieve, or manipulate tissue within the body. It consists of a flexible wire loop, often made of stainless steel or synthetic materials, which are controlled by a handle to securely grasp and cut polyps, lesions, or other abnormal growths. Commonly used in endoscopic surgeries, surgical snares enable precise and controlled removal of tissue while minimizing trauma, reducing recovery time, and enhancing procedural efficiency in clinical settings.
According to WHO, cancer is the leading cause of death, accounting for nearly 10 million deaths worldwide. The most common type of cancer was breast cancer, accounting for nearly 2.26 million cases, followed by lung and colon cancer, accounting for approximately 2.21 and 1.93 million cases, respectively.
Increasing prevalence of chronic diseases
The growing global burden of chronic diseases such as colorectal cancer, inflammatory bowel disease, and gastrointestinal polyps is significantly boosting the demand for surgical snares. As these conditions often require endoscopic interventions for diagnosis and treatment, the use of surgical snares becomes critical for polyp removal and tissue sampling. Thus this surge in chronic illnesses places pressure on healthcare systems to adopt minimally invasive procedures are fueling the adoption of surgical snares.
High cost of advanced surgical snares
Surgical snares incorporate enhanced materials, ergonomic designs, or innovative features like rotatable tips, tend to be expensive to manufacture and procure. Smaller clinics and healthcare facilities may find it difficult to invest in these tools, opting instead for lower-cost alternatives with fewer capabilities. Additionally, reimbursement challenges and budget constraints further complicate the procurement of advanced surgical equipment.
Expansion into untapped emerging markets
Rapid urbanization, improving healthcare infrastructure, and increasing awareness of gastrointestinal health in emerging economies present substantial opportunities for market growth. Regions such as Latin America, Southeast Asia, and parts of the Middle East are experiencing an uptick in healthcare investments and the establishment of endoscopy centers. As medical tourism grows in these areas, demand for minimally invasive surgical tools like snares is expected to rise and facilitate deeper market penetration and brand recognition.
Strict reimbursement policies
Insurance limitations and complex approval processes can deter hospitals from investing in high-cost endoscopic tools. Additionally, variations in reimbursement policies across different regions create inconsistencies in market accessibility. As governments and insurers emphasize cost-effective treatment options, manufacturers must navigate regulatory hurdles to ensure broader adoption of their products hampering the growth of the market.
The COVID-19 pandemic disrupted the surgical snare market, affecting supply chains and delaying elective procedures. Hospitals prioritized emergency treatments, leading to a temporary decline in demand for endoscopic interventions. However, as healthcare systems adapted, the market rebounded with increased focus on minimally invasive surgeries to reduce hospital stays and infection risks. The pandemic also accelerated technological advancements, prompting manufacturers to develop more efficient and cost-effective surgical snares to meet evolving healthcare needs.
The reusable surgical snares segment is expected to be the largest during the forecast period
The reusable surgical snares segment is expected to account for the largest market share during the forecast period due to their cost-efficiency and long-term usability in clinical settings. Healthcare facilities are increasingly adopting reusable options to reduce operational expenses and minimize medical waste. These snares are often preferred in high-volume hospitals where repeated procedures make reuse more economical.
The cold snare segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the cold snare segment is predicted to witness the highest growth rate owing to their advantages in removing small polyps without the use of electrocautery. This method reduces the risk of thermal injury to surrounding tissues, making it safer for patients with bleeding disorders or those on anticoagulants. The simplicity of the technique also makes it accessible for outpatient procedures, contributing to its rising adoption.
During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by a rapidly growing population, increasing prevalence of gastrointestinal diseases, and rising awareness about early cancer detection. Countries such as China, India, and Japan are seeing increased investments in healthcare infrastructure, particularly in endoscopic technology. Government screening programs and initiatives to promote early diagnosis are further driving the adoption of surgical snares.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to ongoing advancements in endoscopic procedures and robust adoption of minimally invasive technologies. The region benefits from a well-established medical device industry, favorable reimbursement systems, and a high prevalence of colorectal cancer, one of the primary indications for snare polypectomy. Continuous innovation by key market players and strong R&D funding also contribute to the rapid growth.
Key players in the market
Some of the key players in Surgical Snare Market include Zimmer Biomet Holdings, Inc., B. Braun Melsungen AG, Smith & Nephew PLC, FUJIFILM Holdings Corporation, Richard Wolf GmbH, Pentax Medical, Karl Storz SE & Co. KG, Stryker Corporation, Veran Medical Technologies (acquired by Boston Scientific), Sklar Surgical Instruments, Medtronic PLC, Olympus Corporation, Steris PLC, Boston Scientific Corporation, Merit Medical Systems, Inc., Avalign Technologies, Inc., Hill-Rom Holdings, CONMED Corporation, and Medline Industries.
In May 2025, Richard Wolf GmbH entered into an agreement with Photocure to develop a high-definition flexible blue light cystoscope for global commercialization.
In May 2025, Merit Medical Systems, Inc. acquired Biolife Delaware, L.L.C., aiming to enhance its product offerings and improve financial performance.
In April 2025, Zimmer Biomet Holdings, Inc. completed the acquisition of Paragon 28 for approximately $1.1 billion, enhancing its portfolio in foot and ankle surgical devices.